Calcipotriol in the treatment of dermatoses

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Calcipotriol (calcipotriene), a synthetic analog of vitamin D3, is used to treat psoriasis. Calcipotriol inhibits keratinocyte proliferation, accelerates their morphological differentiation, and has crucial immunosuppressive effects. Calcipotriol’s mechanism of action supports its use for the treatment of various disorders, including actinic keratosis, vitiligo, seborrheic keratosis, eczema, acne, alopecia areata, and others.

This work examined the use of calcipotriol in skin diseases, including psoriasis. Furthermore, it assessed the efficacy of calcipotriol and the persistence of clinical effect.

The analysis was based on scientific publications indexed in international databases (Web of Science, Scopus, PubMed) and in the Russian Science Citation Index (RSCI).

The following keywords and their combinations in both Russian and English were used: витамин D (vitamin D), кальцитриол (calcitriol), кальципотриол (calcipotriol), and кальципотриен (calcipotriene). The search depth was 10 years (2014–2024). The search of international publications using the keyword calcipotriol yielded 707 articles. The review included 55 articles published over the last decade.

The search revealed an increasing global interest in the use of calcipotriol in the treatment of various dermatoses. According to research, calcipotriol can be used as adjuvant therapy in a variety of skin diseases, and the indications for this synthetic analog of vitamin D3 are anticipated to expand over time.

The high efficacy and safety of calcipotriol have been demonstrated in numerous studies. However, more extensive research is needed to improve the methods and criteria for its use.

About the authors

Dariya Kairesheva

The First Sechenov Moscow State Medical University

Email: kaireshevadari@gmail.com
ORCID iD: 0009-0008-6336-0069
Russian Federation, Moscow

Marina V. Alekseeva

The First Sechenov Moscow State Medical University

Author for correspondence.
Email: meri.alekseeva@gmail.com
ORCID iD: 0009-0008-0931-2701
Russian Federation, Moscow

Lyailya N. Kayumova

The First Sechenov Moscow State Medical University

Email: avestohka2005@inbox.ru
ORCID iD: 0000-0003-0301-737X
SPIN-code: 4391-9553

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Konstantin M. Lomonosov

The First Sechenov Moscow State Medical University

Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN-code: 4784-9730

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. AlGhamdi K, Kumar A, Moussa N. The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian J Dermatol Venereol Leprol. 2013;79(6):750–758. doi: 10.4103/0378-6323.120720
  2. Beyzaee AM, Goldust M, Patil A, et al. The role of cytokines and vitamin D in vitiligo pathogenesis. J Cosmet Dermatol. 2022;21(11):6314–6325. doi: 10.1111/jocd.15272
  3. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1):23–33. doi: 10.1124/jpet.107.127209
  4. Guilhou JJ. Calcipotriol. Ann Dermatol Venereol. 2001;128(3 Pt 1):229–237. (In French).
  5. Olisova OYu. Modern approaches to the management of patients with psoriasis. Russkii meditsinskii zhurnal. 2004;12(4):182–185. (In Russ.)
  6. Vladimirov VV, Samtsov AV, Gerasimova NM, Nikulin NK. Multicenter study of the clinical efficacy of psorkutan in the treatment of patients with psoriasis. Vestnik dermatologii i venerologii. 1999;(1):50–51. (In Russ.)
  7. Van de Kerkhof PC, Franssen M, de La Brassine M, Kuipers M. Calcipotriol cream in the morning and ointment in the evening: a novel regimen to improve compliance. J Dermatolog Treat. 2001;12(2):75–79. doi: 10.1080/095466301317085345
  8. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150(6):1167–1173. doi: 10.1111/j.1365-2133.2004.05986.x
  9. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82(2):131–135. doi: 10.1080/00015550252948194
  10. Guenther L, van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323. doi: 10.1046/j.1365-2133.2002.04967.x
  11. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393. doi: 10.1159/000066440
  12. Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and safety of different formulations of calcipotriol / betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med. 2021;10(23):5589. doi: 10.3390/jcm10235589
  13. Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599–620. doi: 10.1080/1744666X.2020.1776116
  14. Jo SJ, Park CJ, Bang CH, et al. Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: a prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction. J Dermatol. 2022;49(11):1085–1095. doi: 10.1111/1346-8138.16519
  15. López Estebaranz JL, Kurzen H, Galván J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatolog Treat. 2024;35(1):2357618. doi: 10.1080/09546634.2024.2357618
  16. Staubach P, Körber A, Trüeb RM, et al. A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement. Drugs Context. 2024;13:2024-1-6. doi: 10.7573/dic.2024-1-6
  17. Gerdes S, Campanati A, Ratzinger G, et al. Improvements in plaque psoriasis associated with calcipotriol / betamethasone aerosol foam treatment: a post hoc analysis of non-interventional studies and clinical experience. Dermatol Ther (Heidelb). 2024;14(3):793–804. doi: 10.1007/s13555-024-01108-0
  18. Yang M, Chang JM. Successful treatment of refractory chronic hand eczema with calcipotriol/betamethasone ointment: a report of three cases. Exp Ther Med. 2015;10(5):1943–1946. doi: 10.3892/etm.2015.2729
  19. Juntongjin P, Pongprasert R. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema. Dermatol Ther. 2019;32(4):e12956. doi: 10.1111/dth.12956
  20. Juntongjin P, Chunhakham P. Synergistic effects of the 308-nm excimer light and topical calcipotriol for the treatment of chronic hand eczema: a randomized controlled study. Dermatology. 2021;237(1):31–38. doi: 10.1159/000505539 EDN: OLZQAG
  21. Mahran A, Ghazally A, Ali AS, Bakr RM. Efficacy and safety of calcipotriol as a potential topical treatment of acne vulgaris: a randomized, controlled, triple blinded, split-face clinical trial. Clin Exp Dermatol. 2024;49(4):348–355. doi: 10.1093/ced/llad371 EDN: ZAOXUX
  22. Abdel-Wahab HM, Ali AK, Ragaie MH. Calcipotriol: a novel tool in treatment of acne vulgaris. Dermatol Ther. 2022;35(9):e15690. doi: 10.1111/dth.15690 EDN: ECKGFH
  23. Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Ther. 2017;30(3). doi: 10.1111/dth.12464
  24. Kim DH, Lee JW, Kim IS, et al. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012;24(3):341–344. doi: 10.5021/ad.2012.24.3.341
  25. Çerman AA, Solak SS, Altunay İ, Küçükünal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14(6):616–620.
  26. Molinelli E, Campanati A, Brisigotti V, et al. Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata: an intrasubject pilot study. Dermatol Ther (Heidelb). 2020;10(3):515–521. doi: 10.1007/s13555-020-00379-7 EDN: ULGJWZ
  27. Alam M, Amin SS, Adil M, et al. Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata. Int J Trichology. 2019;11(3):123–127. doi: 10.4103/ijt.ijt_18_19
  28. Nassar A, Elradi M, Radwan M, Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: a clinical and trichoscopic study. J Cosmet Dermatol. 2023;22(4):1297–1303. doi: 10.1111/jocd.15558 EDN: YBNSLE
  29. Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106–116. doi: 10.1172/JCI89820
  30. Azin M, Mahon AB, Isaacman S, et al. Topical calcipotriol plus 5-fluorouracil immunotherapy for actinic keratosis treatment. JID Innov. 2022;2(3):100104. doi: 10.1016/j.xjidi.2022.100104 EDN: WIWCPJ
  31. Moore AY, Nguyen M, Moore S. Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: a retrospective study. J Am Acad Dermatol. 2021;84(4):1148–1150. doi: 10.1016/j.jaad.2020.07.010 EDN: BTIEDT
  32. Rosenberg AR, Tabacchi M, Ngo KH, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019;4(6):e125476. doi: 10.1172/jci.insight.125476
  33. Galimberti GN. Calcipotriol as pretreatment prior to daylight-mediated photodynamic therapy in patients with actinic keratosis: a case series. Photodiagnosis Photodyn Ther. 2018;21:172–175. doi: 10.1016/j.pdpdt.2017.11.019
  34. Seo JW, Song KH. Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades III-V skin: a prospective randomized clinical trial. J Am Acad Dermatol. 2018;78(4):795–797. doi: 10.1016/j.jaad.2017.11.027
  35. Torezan L, Grinblat B, Haedersdal M, et al. A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis. Br J Dermatol. 2018;179(4):829–835. doi: 10.1111/bjd.16473
  36. Milde P, Hauser U, Simon T, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol. 1991;97(2):230–239. doi: 10.1111/1523-1747.ep12480255
  37. Gong Q, Li X, Sun J, et al. The effects of calcipotriol on the dendritic morphology of human melanocytes under oxidative stress and a possible mechanism: is it a mitochondrial protector? J Dermatol Sci. 2015;77(2):117–124. doi: 10.1016/j.jdermsci.2014.12.006 EDN: FZKKDE
  38. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9(4):345–359. doi: 10.2174/138945008783954970
  39. Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21(2):79–83. doi: 10.1111/j.1600-0781.2005.00139.x
  40. Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(5):553–557. doi: 10.1111/j.1468-3083.2006.01546.x
  41. Bakr RM, Abdel-Gaber RM, Tawfik YM. A comparative study on the use of fractional CO2 laser with tacrolimus or calcipotriol or narrow band ultraviolet-B in treatment of stable nonsegmental vitiligo. Dermatol Ther. 2021;34(1):e14604. doi: 10.1111/dth.14604 EDN: BAWCIN
  42. Ibrahim ZA, Hassan GF, Elgendy HY, Al-Shenawy HA. Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo. J Cosmet Dermatol. 2019;18(2):581–588. doi: 10.1111/jocd.12704
  43. Liu X, Yao Z, Wang Y, et al. Vitamin D analogs combined with different types of phototherapy in the treatment of vitiligo: a systematic review of randomized trials and within-patient studies. Int Immunopharmacol. 2022;109:108789. doi: 10.1016/j.intimp.2022.108789 EDN: DPEBCD
  44. Abd Elazim NE, Kamal A, Abdel Gaber RM, et al. Efficacy of topical calcipotriol betamethasone dipropionate as a new adjuvant therapy to follicular unit extraction technique in treatment of stable vitiligo: clinical, dermoscopic and immunohistological study. J Cosmet Dermatol. 2021;20(9):2894–2905. doi: 10.1111/jocd.13922 EDN: XTKPNE
  45. Juntongjin P, Sangganjanavanich P. Efficacy of the combined excimer light and topical calcipotriol for acral vitiligo: a randomized double-blind comparative study. Dermatol Ther. 2021;34(2):e14886. doi: 10.1111/dth.14886 EDN: KXKBPQ
  46. Li C, Hu Y, Mu Z, et al. Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis. J Dermatolog Treat. 2024;35(1):2302064. doi: 10.1080/09546634.2024.2302064 EDN: JSYBDH
  47. Hu M, Liao K, Lei W, et al. The addition of topical calcipotriol to phototherapy enhance the efficacy of treatment in patients with vitiligo: a systematic review and meta-analysis. Int Immunopharmacol. 2021;98:107910. doi: 10.1016/j.intimp.2021.107910 EDN: IQUJSD
  48. Di Guida A, Fabbrocini G, Patruno C, Napolitano M. Hailey-Hailey disease treated successfully with calcipotriol plus betamethasone dipropionate aerosol foam: a case report. Dermatol Ther. 2021;34(1):e14654. doi: 10.1111/dth.14654 EDN: CELEZF
  49. Martora F, Ruggiero A, Fornaro L, et al. Photodynamic therapy with 16 methyl aminolaevulinic acid and topic calcipotriol: a novel promising synergistic approach for the management of Hailey-Hailey disease. Photodiagnosis Photodyn Ther. 2022;39:103018. doi: 10.1016/j.pdpdt.2022.103018 EDN: JWQZAI
  50. Drozhdina MB, Koshkin SV. Review of modern techniques and analysis of patient outcomes with benign familial pemphigus Gougereau-Haley-Haley. Vestnik dermatologii i venerologii. 2024;100(6):70–80. doi: 10.25208/vdv16783 EDN: QEKIIZ
  51. Yap FB. The role of combination calcipotriol plus betamethasone dipropionate gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis. Sultan Qaboos Univ Med J. 2018;18(4):e520–e523. doi: 10.18295/squmj.2018.18.04.015
  52. Patel RT, Fagan KK, Quan EY, et al. Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream for the treatment of cutaneous in situ squamous cell carcinoma: a pilot study. J Am Acad Dermatol. 2024;91(6):1277–1278. doi: 10.1016/j.jaad.2024.08.039 EDN: DTQFCG
  53. Guttmann-Gruber C, Piñón Hofbauer J, Tockner B, et al. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: a randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2021;16(1):473. doi: 10.1186/s13023-021-02062-2 EDN: OAEGOW
  54. Wang RN, Zhang PS, Zhu XF. Bilateral hyperkeratosis of the nipples and areolae with linear nevus and acanthosis nigricans: a rare case report. Skin Health Dis. 2024;4(2):e344. doi: 10.1002/ski2.344 EDN: INYUUD
  55. Popadic S, Tomanovic M, Minic S. Effectiveness and safety of topical calcipotriol in the treatment of flat seborrheic keratosis on the face. Australas J Dermatol. 2023;64(2):e171–e174. doi: 10.1111/ajd.13997 EDN: QLHCVJ

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».